Floatz logo

Therapeutic Asset Ratings

178 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Capecitabine
Pancreatic Adenocarcinoma
Zhejiang UniversityP4BB (68)
Capecitabine
Metastatic Pancreatic Carcinoma
Zhejiang UniversityP2BB (68)
Cetuximab
Colorectal Neoplasms
Zhejiang UniversityP4BB (66)
Cyclophosphamide
Biliary Tract Cancer
Zhejiang UniversityP3BB (66)
Bortezomib
Stage IV Pancreatic Cancer
Zhejiang UniversityP2BB (66)
Cyclophosphamide
Castration-Resistant Prostate Carcinoma
Zhejiang UniversityP2BB (66)
INDOMETACINUM
Prostate Cancer (Post Prostatectomy)
Zhejiang UniversityP2B (63)
DEXAMETHASONE
Ovarian Neoplasms
Zhejiang UniversityP3B (62)
Levoleucovorin
Metastatic Pancreatic Cancer
Zhejiang UniversityP2B (62)
Cetuximab
BRAF
Zhejiang UniversityP2B (60)
Dasatinib
Non-Hodgkin's Lymphoma
Zhejiang UniversityP2B (60)
Carboplatin
Pancreatic Adenocarcinoma
Zhejiang UniversityP2B (59)
Dfn-15
Rectal Cancer
Zhejiang UniversityP3B (58)
Tucidinostat
T Lymphoblastic Leukemia/Lymphoma
Zhejiang UniversityP2B (57)
cll1 car t-cells
AML
Zhejiang UniversityP2/3B (57)
Fludarabine
Castration-Resistant Prostate Cancer (CRPC)
Zhejiang UniversityP1/2B (56)
ibi343
Pancreatic Cancer
Zhejiang UniversityP3CCC (54)
Fruquintinib
Colorectal Neoplasms
Zhejiang UniversityP2CCC (54)
Adebellizumab
Neoadjuvant Chemotherapy
Zhejiang UniversityP2CCC (53)
Adebellizumab
Resectable Pancreatic Cancer
Zhejiang UniversityP2CCC (53)
Bcma Car-T Cells
New Diagnosis Tumor
Zhejiang UniversityP2CCC (53)
Capecitabine
MSI-L
Zhejiang UniversityP2CCC (53)
cd19-ucart
Large B-Cell Lymphoma (LBCL)
Zhejiang UniversityP2CCC (53)
Cetuximab
Cetuximab N01
Zhejiang UniversityP2CCC (53)
Cetuximab
Cetuximabβ
Zhejiang UniversityP2CCC (53)
Showing 1 to 25 of 178 assets
PreviousPage 1 of 8Next